Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Stitute for form 1449A/PTO

MFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

	Complete if Known	RECEIVED
Application Number	09/881,050	- VEIVED
Filing Date	June 15, 2001	SEP 9 a
First Named Inventor	Croze et al.	SEP 2 6 2002
Group Art Unit	Unassigned	TECHARITIES
Examiner Name	Unassigned	TECH CENTER 1600/2900
Attorney Docket Number	Berlx-88	00/2900

	U.S. PATENT DOCUMENTS						
-		U.S. Patent Document		Name of Patentee or Applicant	Date of Publication of		
Examiner Cite Initials * No.1	Number Kind Code ² (if known)		of Cited Document	Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevan Passages or Relevant Figures Appear		
	 	 					
	<u> </u>						
		 			ļ		
	 	 					
							
		 					
		<u> </u>					
					<u> </u>		
·							
		ļ					
		ļ					

FOREIGN PATENT DOCUMENTS								
Examiner	Cite	Foreign Patent Document			Name of Patentee	Date of Publication of	Pages, Columns, Lines,	ļ
Initials*	No.1	Office ³	Number ⁴	Kind Code ⁵ (<i>if known</i>)	or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T ₆
0//-	1	wo	00 17361			03-30-2000		
7	2	wo	95 30435			11-16-1995		
	3	WO	99 62542			12-09-1999		
	4	WO	99 29863			06-17-1999		
V	5	wo	01,79289			10-25-2001		
		-						
		-						
						 		

Examiner Signature	11 II- (In)	Date Considered	12 A & ron

EXAMINER: Initial if eference considered, whether or not citation is in conformance with MPEP 609. Draw line thready citation if not in conformance and not considered include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark hee if English language Translation is attached.

3			
7	ype a plus sign (+) inside this box	>	+

PTO/SB/08A (08-00)
 488488888888888

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Complete if Known

09/881,050

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Application Number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Filing Date

June 15, 2001

First Named Inventor

Croze et al.

Group Art Unit

Unassigned

Examiner Name

Unassigned

(use as many sheets as necessary)

2 of 2

Sheet

Examiner Name
Attorney Docket Number

Berlx-88 TECH CENTER 1620/2900

	_	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2	
(/L	6	H.S. PANITCH ET AL., "CLINICAL TRIALS OF INTERFERONS IN MULTIPLE SCLEROSIS: WHAT HAVE WE LEARNED?" JOURNAL OF NEUROIMMUNOLOGY, July 1, 1993, Vol. 46, No. ½, pp. 155-164		
7	7	JOHNSON, K.P., "ROLE OF INTERFERONS IN DEMYELINATING DISEASE", <u>JOURNAL OF NEURAL</u> TRANSMISSION, SUPPLEMENTUM, 1997, Vol. 49,pp. 111-115		
		,		

Examiner Signature	0/12/11	Date Considered (2 / 1 2 -

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line though citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.